Mongolia vs Sudan: Average cost of drugs for extensively drug-resistant tuberculosis
Mongolia
1,900 constant 2022 US$
in 2024
Sudan
1,962 constant 2022 US$
in 2023
Mongolia rank
28th
Sudan rank
26th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Mongolia
- Sudan
How they compare
Sudan currently reports 1,962 constant 2022 US$ against 1,900 constant 2022 US$ in Mongolia, a difference of 62 constant 2022 US$.
The two have swapped places 3 times across 6 shared years of data; in 2018 it was Mongolia ahead.
Mongolia ranks 28th and Sudan ranks 26th of 56 countries.
Mongolia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Mongolia | Sudan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 13,000 constant 2022 US$ | 5,080 constant 2022 US$ | 7,920 constant 2022 US$ | Mongolia |
| 2020s | 2,175 constant 2022 US$ | 1,672 constant 2022 US$ | 503.5 constant 2022 US$ | Mongolia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Mongolia or Sudan?
- Sudan, at 1,962 constant 2022 US$ against 1,900 constant 2022 US$ in Mongolia as of 2023.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Mongolia and Sudan?
- 62 constant 2022 US$, with Sudan ahead.
- How many years of comparable data are there for Mongolia and Sudan?
- 6 years are reported by both, from 2018 to 2023.
- How do Mongolia and Sudan rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Mongolia ranks 28th and Sudan ranks 26th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.